Clinical Trial Update: Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the safety and efficacy of EB-203 for neovascular age-related macular degeneration is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• EB-203

Snippet

Sponsor: EyebioKorea, Inc. | Conditions: Neovascular Age-related Macular Degeneration (nAMD) | Phase 2 | Status: RECRUITING